Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcriptClaire Lucas, R E Clark|Haematologica|2009Cited by 118
High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemiaClaire Lucas, Shankar Varadarajan|Leukemia|2016Cited by 27